About InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Lecanemab making it ideal for research use. This Lecanemab biosimilar is a recombinant humanized IgG1 antibody directed against aggregated soluble and insoluble forms of amyloid-beta (Aβ), which are implicated in the pathophysiology of Alzheimer’s disease. Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain with high selectivity to Aβ protofibrils. InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman amyloid-beta Reported ApplicationsFunctional assays FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
